EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

Combination of rituximab and methotrexate followed by rituximab and cytarabine in elderly patients with primary central nervous system lymphoma

Jun Ho Yi iD, Seok Jin Kim, Deok-Hwan Yang iD, Young Rok Do, Jong Ho Won, Dongwon Baek iD, Ho Jin Shin, Dae Sik Kim iD, Hyo Jung Kim, Ka-Won Kang iD, Sung Hwa Bae, Ji-Hyun Kwon und 3 weitere

British Journal of Haematology · 2024-11 · 205 (5) · 1773-1781

DOI: 10.1111/bjh.19659 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift British Journal of Haematology, online erschienen am 05.08.2024. Verfasst von Jun Ho Yi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Chung-Ang University Hospital, Seoul, Korea. Hauptthemen laut MEDLINE: Rituximab, Methotrexate, Cytarabine, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The optimal treatment strategy for newly diagnosed primary central nervous system lymphoma (PCNSL) has yet to be established, especially in the elderly. In the current study, we conducted a phase II study to evaluate the efficacy and safety of rituximab plus high‐dose MTX followed by rituximab plus cytarabine in patients aged ≥60 years newly diagnosed with PCNSL. Patients received an induction treatment of high‐dose methotrexate plus rituximab followed by two cycles of a consolidation treatment of cytarabine plus rituximab. The primary end‐point was a 2‐year progression‐free survival (PFS) rate. A total of 35 patients were recruited, and their median age was 73 (range: 60–81). After induction treatment, the complete and partial responses (PRs) were 56% and 20% respectively. Twenty‐six patients proceeded to the consolidation treatment; the complete and PRs were 59% and 9% respectively. After a median follow‐up duration of 36.0 months, the 2‐year PFS rate was 58.7%. Treatment was generally well‐tolerated as only three patients were withdrawn from the study due to toxicity, and no treatment‐related mortality was reported. The 2‐year overall survival rate was 77.9%. The current study may suggest the feasibility of administering high‐dose MTX plus cytarabine in PCNSL patients aged ≥60 years and the potential role of additive rituximab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabMethotrexateCytarabineAntineoplastic Combined Chemotherapy ProtocolsCentral Nervous System NeoplasmsHumansAgedMaleFemaleMiddle AgedAged, 80 and overLymphoma

Stichwörter der Autor:innen

cytarabineelderly patientsmethotrexateprimary central nervous system lymphomarituximab

Substanzen

RituximabMethotrexateCytarabine

Autor:innen und Institutionen

  • Department of Internal Medicine, Chung-Ang University Hospital, Seoul, Korea.
  • Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Department of Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun, Korea.
  • Department of Medicine, Dongsan Medical Center, Daegu, Korea.
  • Department of Hematology-Oncology, Soonchunhyang University Hospital, Soonchunhyang University College of Medicine, Seoul, Korea.
  • Department of Hematology-Oncology, Kyungpook National University Hospital, Kyungpook National University, Daegu, Korea.

ORCID-Profile: Jun Ho Yi, Deok-Hwan Yang, Dongwon Baek, Dae Sik Kim, Ka-Won Kang

Zitieren

APA

Yi, J. H., Kim, S. J., Yang, D. H., Do, Y. R., Won, J. H., Baek, D., Shin, H. J., Kim, D. S., Kim, H. J., Kang, K. W., Bae, S. H., Kwon, J. H., Kwon, J. H., Park, B. B., & Kim, W. S. (2024). Combination of rituximab and methotrexate followed by rituximab and cytarabine in elderly patients with primary central nervous system lymphoma. British Journal of Haematology, 205(5), 1773-1781. https://doi.org/10.1111/bjh.19659

Vancouver

Yi JH, Kim SJ, Yang DH, Do YR, Won JH, Baek D, et al. Combination of rituximab and methotrexate followed by rituximab and cytarabine in elderly patients with primary central nervous system lymphoma. British Journal of Haematology. 2024;205(5):1773-1781. doi:10.1111/bjh.19659

BibTeX
@article{Yi2024,
  author = {Yi, Jun Ho and Kim, Seok Jin and Yang, Deok-Hwan and Do, Young Rok and Won, Jong Ho and Baek, Dongwon and Shin, Ho Jin and Kim, Dae Sik and Kim, Hyo Jung and Kang, Ka-Won and Bae, Sung Hwa and Kwon, Ji-Hyun and Kwon, Jung Hye and Park, Byeong Bae and Kim, Won Seog},
  title = {Combination of rituximab and methotrexate followed by rituximab and cytarabine in elderly patients with primary central nervous system lymphoma},
  journal = {British Journal of Haematology},
  year = {2024},
  volume = {205},
  number = {5},
  pages = {1773--1781},
  doi = {10.1111/bjh.19659}
}
Kostenlos starten →